ArticleAdvances in therapy2022

Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.

Jianming He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.